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Fibrinogen (Fg) is significantly up-regulated in the
kidney after acute kidney injury (AKI). We evaluated
the performance of Fg as a biomarker for early detec-
tion of AKI. In rats and mice with kidney tubular
damage induced by ischemia/reperfusion (I/R) or cis-
platin administration, respectively; kidney tissue and
urinary Fg increased significantly and correlated with
histopathological injury, urinary kidney injury mole-
cule-1 (KIM-1) and N-acetyl glucosaminidase (NAG)
corresponding to the progression and regression of
injury temporally. In a longitudinal follow-up of 31
patients who underwent surgical repair of abdominal
aortic aneurysm, urinary Fg increased earlier than
SCr in patients who developed postoperative AKI
(AUC-ROC  0.72). Furthermore, in a cohort of pa-
tients with biopsy-proven AKI (n  53), Fg immuno-
reactivity in the tubules and interstitium increased
remarkably and was able to distinguish patients with
AKI from those without AKI (n  59). These results
suggest that immunoreactivity of Fg in the kidney, as
well as urinary excretion of Fg, serves as a sensitive
and early diagnostic translational biomarker for de-
tection of AKI. (Am J Pathol 2012, 181:818–828; http://dx.
doi.org/10.1016/j.ajpath.2012.06.004)
818Acute kidney injury (AKI) is a common disorder that por-
tends adverse outcomes in critically ill and non-critically
ill hospitalized patients.1–3 Serum creatinine (SCr) and
blood urea nitrogen (BUN) are most commonly used to
detect kidney injury in preclinical and clinical studies and
in routine clinical care, but have severe limitations in
terms of sensitivity and specificity.4,5 Furthermore, BUN
and SCr concentrations render a very delayed signal,
even after considerable kidney injury, and this delay in
the diagnosis of AKI prevents timely patient-management
decisions, such as withdrawal or reduction in dose of the
toxic agent or administration of therapeutics to mitigate
the injury.6,7 Recent international efforts in biomarker
identification and evaluation have resulted in the qualifi-
cation of a subset of second-generation biomarkers for
preclinical studies that can outperform or add significant
value to existing conventional biomarkers.6,8 Significant
effort is continuously being expended not only in evalu-
ating the existing biomarkers in human studies for early
detection of AKI, but also in identifying newer, more sen-
sitive biomarkers as a part of the rolling biomarker qual-
ification process.9
Previous research in our laboratory identified urinary
fibrinogen (Fg) to be significantly up-regulated after kid-
ney ischemia/reperfusion (I/R)-induced injury in rats,
compared with controls, as well as in patients with clini-
cally established multifactorial AKI, compared with
healthy volunteers.10 These observations were consistent
with published reports showing a positive correlation be-
tween urinary fibrin degradation products and proteinuria
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radation products in combination with N-acetyl--D-glu-
cosaminidase (NAG) were also shown to allow a diagno-
sis of 25 out of 26 acute rejection episodes at least 24
hours before deterioration in renal function. Furthermore,
this elevation of fibrin degradation products preceded
the rise in NAG in 9 of 11 patients.12 Thus far, however,
studies have lacked the ability to systematically and com-
prehensively evaluate the performance of Fg excretion in
the urine and its immunostaining patterns in kidney as
translational biomarker for early, sensitive, and specific
detection of AKI.
The objective of the present study was to characterize
the expression and excretion pattern of Fg relative to
BUN, SCr, kidney injury molecule-1 [KIM-1; also known
as hepatitis A virus cellular receptor 1 homolog (HAVcr-
1)], and N-acetyl--D-glucosaminidase (NAG) and to per-
form histopathological analysis using mechanistically dis-
tinct forms of AKI in mice, rats, and humans. Specifically,
our aims were to evaluate i) the diagnostic performance
of urinary Fg after 30-minute bilateral renal I/R-induced
reversible injury in rats and cisplatin (20 mg/kg, i.p.)-
induced irreversible acute nephrotoxicity in mice; ii) the
specificity of urinary Fg in detecting AKI using a well-
established, galactosamine (1.1 g/kg, i.p.)-induced liver
injury model13; iii) the predictive potential of urinary Fg as
an AKI diagnostic biomarker in humans using a longitu-
dinal follow up of patients who developed AKI after sur-
gery of abdominal aortic aneurysms; and iv) the utility of
Fg immunostaining patterns in differentiating patients
with or without AKI.
Materials and Methods
Animals
Animals were maintained in a central animal facility over
wood chips free of any known chemical contaminants
under conditions of 21  1°C and 50% to 80% relative
humidity at all times in an alternating 12 hours light-dark
cycle. Animals were fed with commercial rodent chow
and given water ad libitum; animals were acclimated for 1
week before use. All animal maintenance and treatment
protocols were in compliance with the Guide for Care and
Use of Laboratory Animals as adopted and promulgated
by the National Institutes of Health and were approved by
the Harvard Medical School Institutional Animal Care and
Use Committee.
Bilateral Renal I/R
Male Wistar rats (280 to 320 g) were subjected to I/R by
clamping both renal arteries under anesthesia (30 mg/kg
pentobarbital, i.p.) for 30 minutes, as described previ-
ously.5 Rats were euthanized by an overdose of pheno-
barbital (180 mg/kg) and were sacrificed at 3, 6, 12, 18,
24, 72, 120, and 168 hours after reperfusion (n  4).
Sham-surgery rats underwent anesthesia and a laparot-
omy only and were sacrificed after 24 hours and used as
controls.Cisplatin-Induced Kidney Toxicity
Male BALB/c mice (25 to 29 g) were treated with a single
intraperitoneal injection of 20 mg/kg cisplatin (Sigma-
Aldrich, St. Louis, MO) in 0.9% saline solution. Mice were
euthanized by an overdose of phenobarbital (180 mg/kg)
and were sacrificed at 24, 48, or 72 hours after cisplatin
administration (n  5). Control animals were injected with
equal volume of 0.9% saline solution and were eutha-
nized on day 1.
Galactosamine-Induced Liver Toxicity
To determine the specificity of Fg as a biomarker for
kidney damage, male Sprague-Dawley rats (Harlan Lab-
oratories, Frederick, MD) received a single intraperito-
neal injection of either 1.1 g/kg of galactosamine or 0.9%
saline solution (n  6). At 24 hours after galactosamine
injection, rats were euthanized by inhalation overdose of
isoflurane.
Urine and Blood Collection
At approximately 16 hours (for rats) or 4 hours (for mice)
before sacrifice, animals were placed in metabolic cages
and urine was collected by adding RNAlater stabilization
reagent (1 mL for rats; 40 L for mice) to the urine
collection tube. After collection, urine was centrifuged for
10 minutes at 12,000 g at 4°C and aliquots were stored
at 80°C. Blood was collected in heparinized tubes (for
plasma collection) and nonheparinized tubes (for serum
collection). After centrifugation at 12,000  g for 10 min-
utes at 4°C, plasma was collected and stored in aliquots
at 80°C.
Clinical Chemistry, Histopathology, and
Histology Scoring
SCr was measured using a Beckman Creatinine Analyzer
II and urine creatinine (uCr) was measured using a cre-
atinine assay kit (Cayman Chemical, Ann Arbor, MI),
according to the manufacturers’ protocols. BUN was
measured spectrophotometrically at 340 nm using a
commercially available kit (Thermo Fisher Scientific,
Rockford, IL), as described previously.14
Sagittal sections of kidney and liver were placed in
10% neutral buffered formalin and embedded into paraf-
fin. For histological evaluation, embedded tissues were
cut into 4- to 6-m sections and stained with H&E. The
sections were evaluated under a light microscope by a
pathologist (V.B.) in a masked manner, and a severity
score grading scale of 0 to 3 was used to grade patho-
logical lesions: 0, no lesions to minimal; 1, mild acute
tubular injury manifested by mild tubular distension, a low
epithelial lining, and nonspecific degenerative changes
of the epithelial cells; 2, moderate acute tubular injury,
with frequent single cell necrosis within the epithelial lay-
er; and 3, severe acute tubular injury, demonstrated by
the presence of widespread epithelial cell necrosis, low
epithelial lining, and accumulation of cellular debris in the
tubule lumens.
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Urinary KIM-1 was measured using established Luminex-
based assays.4,5 Levels of KIM-1 in mice urine were
determined using a Luminex-based assay recently es-
tablished by the Bonventre Laboratory (Brigham and
Women’s Hospital, Boston, MA). Urinary NAG was mea-
sured spectrophotometrically using a commercially avail-
able kit according to the manufacturer’s instructions
(Roche Diagnostics, Basel, Switzerland). Fg protein in
urine of humans, rats, and mice was measured using
commercially available species-specific Luminex-based
assay kits from Millipore (Billerica, MA).10 This assay
uses two polyclonal antibodies as capture and detecting
antibodies, respectively, against Fg protein and is there-
fore unable to distinguish between the intact Fg and
intermediates (such as /, /, or the half-molecule of
one each // polypeptide chains) or other fibrin deg-
radation products and fibrin-derived peptides.
RNA Extraction and Quantitative Real-Time PCR
At necropsy, tissue was collected, sliced into small frag-
ments, flash-frozen in liquid nitrogen, and stored at
80°C. Kidneys from rats were macroscopically sepa-
rated into medulla and cortex. Total RNA was isolated
from tissue using a TRIzol-chloroform method as de-
scribed previously.10,14 The concentration of total iso-
lated RNA was measured at 260 nm using a NanoDrop
spectrophotometer (Thermo Fisher Scientific, Wilming-
ton, DE), and integrity was determined by 1% agarose
gel electrophoresis. One microgram of RNA was reverse-
transcribed into cDNA using a QuantiTect reverse tran-
scription kit from Qiagen (Valencia, CA) according to the
manufacturer’s instructions. The expression profiles of
Fg, Fg, Fg, and KIM-1 were evaluated with quantita-
tive real-time PCR using a QuantiFast SYBR Green PCR
kit (Qiagen) on a CFX96 RT-PCR instrument (Bio-Rad
Laboratories, Hercules, CA). Amplification was per-
formed using the following temperature profile: 3 minutes
of enzyme activation at 95°C, followed by 40 cycles of
95°C for 10 seconds and 55°C for 30 seconds. GAPDH
was used as a housekeeping gene. Primer sequences
were as described previously.10
Immunoblotting
Total protein was isolated by homogenization of kidney
tissues in radioimmunoprecipitation assay buffer contain-
ing complete protease inhibitor cocktail tablets (Roche
Applied Science, Indianapolis, IN). Protein concentration
was determined using a Pierce BCA protein assay kit
(Thermo Fisher Scientific, Rockford, IL), according to
manufacturer’s instructions.
Equal amounts of protein were loaded onto 12% poly-
acrylamide gel. The proteins were separated by SDS-PAGE
and transferred to a nitrocellulose membrane. After block-
ing in 5% blotting-grade blocker nonfat dry milk (Bio-Rad
Laboratories) for 1 hour at room temperature, the mem-
branes were incubated with a polyclonal anti-fibrinogen an-
tibody (1:1000 dilution; Nordic Immunology; Nordic Immu-nological Laboratories, Eindhoven, Netherlands) at 4°C,
overnight. After three washes with Tris-buffered saline/
Tween, the blots were incubated in horseradish peroxidase-
conjugated secondary antibody (GEHealthcare, Little Chal-
font, UK) and developed using an enhanced chemi-
luminescence kit (GE Healthcare) by autoradiography. A
monoclonal anti--actin antibody (Cell Signaling Technol-
ogy, Danvers, MA) was used as a loading control.
Human Studies
Abdominal Aortic Aneurysm
Urine samples were obtained from 31 patients under-
going open surgical repair of abdominal aortic aneurysm
at Brigham and Women’s Hospital. Urine was collected
preoperatively and at multiple time points after aortic
cross-clamping: immediately afterwards and at 2 to 6
hours, 6 to 12 hours, 12 to 24 hours, 24 to 28 hours, 48 to
72 hours, and 72 to 96 hours after clamping. Not all
participants underwent urine sampling at all time points,
because of clinical circumstances. Urine was collected
from the urometer of a Foley catheter or from spontane-
ous voids in the postoperative setting. Urine samples
were centrifuged at 5000  g for 5 minutes and super-
natants were aliquoted and frozen at 80°C within 6
hours of collection. The Institutional Review Board ap-
proved the protocols for recruitment and sample collec-
tion.
Kidney Biopsy Specimens from Patients With and
Without AKI
Pathology reports, finalized between January 2008
and March 2011 at Brigham and Women’s Hospital and
pertinent to patients who underwent the native kidney
biopsy procedure for medical kidney disease, were
retrieved using the hospital electronic reporting sys-
tem. Cases with the primary diagnosis of acute tubular
necrosis were selected; however, patients with con-
comitant glomerular pathological findings, significant
acute interstitial nephritis, and significant chronic dam-
age (defined as 20% of global glomerulosclerosis or
tubulointerstitial scarring) were excluded. The cases
that did not have adequate frozen tissue with 5 glom-
eruli in the sample submitted for immunofluorescence
studies were also excluded. In all, 53 cases of acute
tubular necrosis were available for the present study.
For a control group, 59 cases with minimal or mild
histological alterations were selected. The control
cases all had adequate frozen tissue for immunofluo-
rescence studies and comprised 27 cases of thin glo-
merular basement membrane disease and 18, 13, and
2 cases with minimal (10%), 10% to 20%, and 21% to
25% chronic changes (global glomerulosclerosis
and/or tubulointerstitial scarring), respectively, and no
other significant histological abnormalities.
injury. Data are indicated as mean SEM *P 0.05 Student’s t-test. n 4 per
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Using the same database as for the patients with
and without AKI, we identified 14 patients with minimal-
change disease (MCD) with known values of urinary
protein/creatinine ratio and SCr values at the time of
the kidney biopsy. All samples had adequate frozen
tissue material for immunofluorescence studies. Of the
14 patients, 7 had a light-microscopic diagnosis of
acute tubular necrosis and 7 had no significant find-
ings on light microscopy.
Immunofluorescence Staining and Scoring
At Brigham and Women’s Hospital, direct immunoflu-
orescence studies are routinely performed on standard
cryostat sections, using fluorescein isothiocyanate-la-
beled polyclonal antisera specific for human heavy
chains of IgG, IgM, and IgA, kappa and lambda light
chains (IgK and IgL), C3, albumin, and fibrin-related an-
tigens, on all human kidney biopsies, at the time of biopsy
evaluation. Only sections stained for fibrin-related anti-
gens (polyclonal rabbit anti-human antibody; Dako,
Carpinteria, CA) were retrieved from the archives and
were retrospectively reviewed in the present study by a
kidney pathologist (V.B.), using an Olympus BX53 (To-
kyo, Japan) vertical illumination fluorescence micro-
scope.
Frozen sections stained for fibrin-related antigens in
human kidney biopsy samples were examined under an
immunofluorescence microscope and were graded by
pattern of staining, without knowledge of the clinical or
morphological diagnosis. The luminal and apical staining
was graded as 0 (none), 1 (involving rare tubules), or 2
(involving several tubules). The apical staining was
graded as 0 (none), 1 (mild), or 2 (marked). The interstitial
staining was graded as 1 (mild) or 2 (marked); a few
samples that did not demonstrate any interstitial reactivity
were graded as 0 (none). The score (mean  SEM) for
each category was plotted using GraphPad Prism 5 soft-
ware (GraphPad Software, La Jolla, CA).
Statistical Analyses
Results are expressed for individual animals or as means
SEM. Urinary data were normalized to urinary creatinine.
Statistical analyses were performed by Student’s t-test
using Graph Pad Prism 5 software. Statistical signifi-
cance was set at P  0.05. Diagnostic performance was
assessed by taking the area underneath the receiver
operating characteristic curve (AUC-ROC) using Med-
Calc version 9.5.0 surface (Mariakerke, Belgium).
Results
Kidney I/R Injury in Rats Results in Significant
Up-Regulation and Excretion of Fg Correlating
with Histopathological Injury
Thirty minutes of bilateral renal ischemia followed by rep-
erfusion resulted in peak of kidney injury and dysfunctionFigure 1. Urinary Fg increases significantly in rats after 30 minutes of bilat-
eral renal I/R injury, correlating with the progression and resolution of AKI.
A: Kidney injury parameters SCr and BUN were measured in the plasma of
male Wistar rats after 30-minute bilateral renal I/R. B: Representative images
of formalin-fixed, H&E-stained kidney histology sections of sham-treated
versus injured tissue after 24 and 168 hours of reperfusion (n  4 per group)
show different levels of acute tubular injury. Scoring from 0 (no lesions) to 3
(severe acute tubular injury) is as described under Materials and Methods. C:
Western blot analyses for Fg in rat kidney cortex and medulla collected at 24
hours after sham surgery or I/R injury revealed increased immunoreactivity of
Fg- and fibrin-derived peptides in cortex and medulla at 24 hours after I/R
injury, compared with sham surgery.D: Urinary levels of Fg, KIM-1, and NAG
normalized to urinary creatinine over time after I/R injury. Each data point
represents an induvidual animal. Colors and symbols indicate histopathology
scores of acute kidney injury in the kidney. A black line indicates the mean.
E: Urinary Fg levels at early time points (3, 6, 12, and 18 hours) after I/Rgroup.
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histopathological damage (Figure 1, A and B). Kidney
parenchyma revealed extensive tubulointerstitial damage
at 24 hours, particularly prominent at the corticomedul-
lary junction, with marked injury of the S3 segments of the
proximal tubules. The individual tubules showed disten-
sion of their lumens and extensive degenerative changes
of the epithelial cells, with widespread necrosis and col-
lections of cellular debris within the tubule lumens. At 120
hours and 168 hours after reperfusion, kidneys showed
mild tubular distension and prominent reactive changes
in the epithelial cell layer. Occasional mitotic figures were
detected, and the nuclei were enlarged and revealed
prominent nucleoli (Figure 1B).
Significantly elevated mRNA expression of all three
chains (Fg, Fg, and Fg) was observed after I/R in the
rat kidney (Table 1). Among the three chains, Fg
showed the highest expression after 72 hours of reperfu-
sion, with an 26-fold increase in cortex and 75-fold in
medulla, whereas Fg showed only a 5-fold increase in
both medulla and cortex (Table 1). The mRNA up-regu-
lation of Fg was slightly higher in cortex than in medulla.
Immunoreactivity of Fg- and fibrin-derived peptides was
considerably increased in cortex and medulla at 24 hours
after I/R injury, compared with sham surgery (Figure 1C).
Urinary Fg increased significantly after 24 hours (80-
fold) after reperfusion, peaked at 72 hours (315-fold),
and by 120 hours had decreased (50-fold) (Figure 1D).
Urinary excretion of the advanced kidney injury biomark-
ers KIM-1 and NAG showed the highest levels after 24
hours, compared with sham surgery (Figure 1D).
The early diagnostic capability of urinary Fg was as-
sessed using urine samples collected at 3, 6, 12, and 18
hours after 30minutes of bilateral renal I/R injury (Figure 1E).
Urinary Fg excretion was increased as early as 3 hours
(60-fold), sharply escalating at 6 hours (700-fold).
Table 1. mRNA Expression of Fg, Fg, and Fg Significantly In
Injury
Treatment
mRN
Fg
Ischemia/reperfusion, cortex
sham 1.0  0.1
24 hours 3.0  0.6*
72 hours 2.9  0.4*
120 hours 4.4  1.0*
168 hours 4.6  0.1*
Ischemia/reperfusion, medulla
sham 1.0  0.2
24 hours 3.8  0.6*
72 hours 6.1  1.8*
120 hours 5.0  2.1
168 hours 2.9  1.0
Cisplatin, 20 mg/kg
0 hours 1.0  0.0
24 hours 9.6  2.5*
48 hours 27.8  7.0*
72 hours 25.3  2.9*Data are expressed as mean fold change  SEM relative to sham-treated ra
*P  0.05 Student’s t-test.Cisplatin-Induced Nephrotoxicity in Mice
Results in Marked Increase in Fg Corresponding
to Histological Damage
In an irreversible model of kidney injury in mice induced
by a single injection of 20 mg/kg cisplatin, an increase in
SCr and BUN indicative of impaired kidney function was
observed at 24 to 48 hours and peaked at 72 hours
(Figure 2A). Cisplatin-induced tubulointerstitial damage
was most prominent in the superficial renal cortex (Figure
2B). The initial injury was manifested by mild tubular
distension and a low epithelial lining in most tubules;
some tubules revealed vacuolization of cytoplasm (Fig-
ure 2B). At 48 hours, injured tubules also revealed single-
cell death in some tubules, with karyopyknosis and ac-
cumulation of cellular debris in a few tubular lumens.
After 72 hours of cisplatin administration, widespread
epithelial cell necrosis was observed in the kidneys, with
sloughing of the epithelium, denuded tubular basement
membranes, and necrotic debris filling the lumens of
many tubules (Figure 2B).
Increased mRNA expression of Fg, Fg, and Fg in
kidneys of cisplatin-treated mice was detected as early
as 24 hours (Table 1). In contrast to I/R injury, in which
Fg showed the highest elevation among all three chains
in the kidney, administration of cisplatin led to a massive
increase in Fg (250-fold after 72 hours), compared
with Fg (25-fold) and Fg (23-fold). Similar increase
in Fg protein expression in the kidney was observed at 72
hours after cisplatin administration (Figure 2C). Approxi-
mately 70-fold higher levels of urinary Fg were detected
as early as 24 hours after cisplatin administration, corre-
sponding with 30-fold increase in urinary KIM-1 con-
centration, whereas urinary excretion of NAG remained
unchanged (Figure 2D).
after Ischemia/Reperfusion or Cisplatin-Induced Kidney Tubular
ession (fold change relative to sham/0 hours)
Fg Fg Kim-1
1.0  0.1 1.0  0.2 1.0  0.3
2.3  7.6* 17.1  4.0* 364.7  32.8*
6.2  5.9* 8.2  1.1* 208.9  55.1*
3.1  7.8* 13.6  2.2* 125.8  35.4*
9.3  4.0 8.2  1.3 108.5  41.2*
1.0  0.2 1.0  0.2 1.0  0.1
0.2  8.7* 4.8  1.6* 325.9  95.7*
5.6  24.8* 9.6  2.4 318.2  144.3
6.8  23.4 9.6  3.9 159.1  67.6
7.6  11.1* 2.8  0.9 76.7  40.7
1.0  0.5 1.0  0.2 1.0  0.1
1.8  0.3 25.0  7.8* 5.0  1.0*
7.3  6.8* 183.2  46.6* 18.1  4.8*
3.0  7.6* 242.4  32.3* 23.9  2.7*creases
A expr
2
2
2
1
4
7
4
2
1
2ts (I/R) or vehicle-treated mice.
kidney are as indicated in the legend key. A black line indicates the mean.
*P  0.05 Student’s t-test. n  4 per group.
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Injury
To evaluate the specificity of Fg as an AKI biomarker,
rats were treated with galactosamine (1.1 g/kg, i.p.), a
well-established hepatotoxicant. At 24 hours after
galactosamine injection, the liver showed extensive
hepatocellular damage, with a marked increase in the
activity of the liver enzymes alanine aminotransferase
(ALT) and aspartate aminotransferase (AST), but with
no signs of kidney structural or functional damage (Ta-
ble 2). Galactosamine treatment did not lead to any
increase in mRNA levels of Fg, Fg, and Fg in the
kidney, nor in urinary excretion of Fg, thereby suggest-
ing increased urinary Fg to be a specific indicator of
kidney damage (Table 2).
Table 3. Demographic and Clinical Characteristics of 31
Patients Undergoing Abdominal Aortic Aneurysm
Repair
Characteristic AKI No AKI
Sample size n  7 n  24
Age (years) 76.7  6.9 71.4  9.5
Female (%) 42.9 37.5
Diabetes (%) 14.2 25
Hypertension (%) 100 91.7
Juxtarenal or suprarenal (%) 28.6 33.3
Preoperative SCr (mg/mL) 1.5 0.7 1.1  0.4
Preoperative eGRF (mL/min
per 1.73m2)
58.7  37.5 62.2  19.4
Weight (kg) 90.1  12.8 81.5  20.6
Table 2. mRNA Expression of Fg, Fg, and Fg and Urinary
Excretion of Fibrinogen Does Not Increase after
Galactosamine-Induced Liver Toxicity
Measure
Galactosamine treatment
0 g/kg 1.1 g/kg
Histopathological score
Kidney 0 0
Liver 0 2
Clinical chemistry
BUN (mg/dL) 19.9  0.8 19.1  1.1
SCr (mg/dL) 0.5  0.0 0.5  0.0
ALT (U/L) 26.0  1.9 422.8  121.9*
AST (U/L) 42.5  3.9 246.0  57.5
Gene expression, kidney
(fold change relative
to control)
Fg 1.0  0.2 1.2  0.1
Fg 1.0  0.1 1.0  0.0
Fg 1.0  0.1 0.9  0.1
Kim-1 1.0  0.1 1.0  0.1
Urinary excretion
Fg (ng/mg uCr) 201.9 38.1 26.0 26.0
Data are expressed as means  SEM.
*P  0.05 Student’s t-test.
ALT, alanine transaminase; AST, aspartate transaminase; BUN, blood
urea nitrogen; SCr, serum creatinine; uCr, urine creatinine.Figure 2. Urinary Fg increases progressively in mice after irreversible kidney
toxicity induced by cisplatin. A: Kidney injury parameters SCr and BUN were
measured in the plasma of male BALB/c mice administered 20 mg/kg cis-
platin. B: Representative formalin-fixed, H&E-stained kidney histology sec-
tions of vehicle- versus cisplatin-treated mice after 24, 48, and 72 hours (n 
5 per group) show different levels of acute tubular injury. Scoring from 0 (no
lesions) to 3 (severe acute tubular injury) is as described underMaterials and
Methods. C: Western blot analyses for Fg in mice kidney lysates at 72 hours
(peak of injury) after cisplatin administration revealed increase in Fg protein
expression. D: Urinary levels of Fg, KIM-1, and NAG normalized to urinary
creatinine over time after cisplatin administration. Each data point represents
an individual animal. Histopathology score of acute tubular injury in theCross-clamp time (min) 80.9 27.3 48.9  19.9
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Postoperative AKI after Abdominal Aortic
Aneurysm
Of 31 patients undergoing abdominal aortic aneurysm
repair, 7 developed postoperative AKI as defined as
50% rise in SCr. Demographic characteristics of pa-
tients according to their AKI status are shown in Table 3.
Among the seven patients with postoperative AKI, SCr
levels tended to rise to50% of baseline values within 48
hours after surgery, whereas urinary Fg, KIM-1, and NAG
showed an earlier increase (Figure 3). The diagnostic
Figure 3. Urinary Fg shows earlier increase among patients with postoper-
ative AKI after abdominal aortic aneurysm, compared with SCr. Shown are
SCr levels in comparison with urinary KIM-1, Fg, and NAG normalized to
urinary creatinine in seven patients who developed AKI (50% rise in SCr
over baseline). An arrow indicates the rise in SCr that occurred by 48 hours
over baseline. Data are expressed as means  SEM. n  7.
Table 4. Comparative Diagnostic Performance Characteristics of
Time (hours)
AUC-ROC
Fg KIM
Preoperative 0.56 (0.36–0.74) 0.52 (0.3
Postoperative 0.68 (0.48–0.84) 0.66 (0.4
2–6 0.63 (0.42–0.81) 0.75 (0.5
6–12 0.52 (0.26–0.77) 0.58 (0.3
12–24 0.65 (0.44–0.83) 0.64 (0.4
24–48 0.72 (0.53–0.87) 0.55 (0.3
48–72 0.70 (0.51–0.85) 0.52 (0.3
72–96 0.61 (0.40–0.79) 0.51 (0.3AUC-ROC, area under the receiver operating characteristic curve.ability of Fg, KIM-1, and NAG to identify AKI versus no
AKI is shown in Table 4. The AUC-ROC exceeded 0.7 for
each biomarker at different time points (24 to 48 hours
and 48 to 72 hours for Fg, 2 to 6 hours for KIM-1, and 6
to 12 hours for NAG).
Immunostaining Patterns of Fg as an Indicator
of Kidney Tubular Damage in Patients with
Biopsy-Proven Acute Tubular Injury
Morphological diagnosis of acute tubular necrosis (ATN)
in human kidney biopsy samples was established based
on light microscopic findings. In the absence of kidney
injury, the tubules were closely packed together, back to
back, and revealed preserved cellular details (Figure
4A), whereas a low epithelial lining and dilatation of the
tubules with accumulation of necrotic cells and cellular
debris in their lumens, as well as mild interstitial edema,
was observed in all cases of acute tubular injury (Figure
4B). Immunoreactivity for Fg/fibrin-related antigens was
examined in all compartments of kidney parenchyma in-
cluding glomeruli, tubules, interstitium, and vasculature.
There was no evidence of Fg immunoreactivity in the
glomerulus or vasculature; in particular, there were no
signs of vascular or glomerular thrombosis or segmental
fibrinoid necrosis in any of the cases examined. A dis-
tinctly differential immunostaining pattern in the luminal
and apical region of the tubules was noted in patients
with ATN (n  53) or without ATN (n  59) (Figure 4, C to
F). Fine granular reactivity in the apical region of the
tubular epithelial cell cytoplasm was noted, which be-
came much more pronounced and widespread in the
ATN patients and was sometimes, but not necessarily,
observed in association with tubular distension and/or
luminal staining (Figure 4, F and I). Luminal staining was
characterized by the reactivity of accumulated intralumi-
nal Fg, which usually consisted of cellular debris ad-
mixed with proteinaceous material. There was a signifi-
cant increase in luminal immunoreactivity of Fg in ATN
patients, compared with those without ATN (Figure 4, C
and I). Interstitial staining for Fg was observed in the vast
majority of the biopsies, which also showed increased
immunoreactivity in the patients with AKI, compared with
those without AKI (Figure 4, H and I).
Biomarkers for the Identification of Established AKI
I) Patients (no.)
NAG AKI No AKI
) 0.55 (0.36–0.73) 7 22
) 0.62 (0.42–0.79) 6 23
) 0.51 (0.30–0.71) 5 20
) 0.75 (0.48–0.93) 4 12
) 0.52 (0.31–0.72) 6 20
) 0.61 (0.42–0.78) 7 24
) 0.51 (0.32–0.70) 6 24
) 0.45 (0.32–0.74) 5 21Urinary
(95% C
-1
3–0.71
6–0.82
4–0.90
2–0.82
3–0.82
7–0.73
4–0.71
0–0.71
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Patients with MCD Who Develop AKI from
Those Who Do Not Develop AKI
The samples from patients with MCD did not reveal sig-
nificant glomerular pathology under light microscopy
(Figure 5, A and C), but all samples demonstrated diffuse
Figure 4. Comparison of Fg immunostaining patterns in human kidney
biopsies in patients with and without AKI. Shown are representative photo-
micrographs of H&E-stained (A and B) and Fg immunofluorescent-stained
(C–H) formalin-fixed, paraffin-embedded kidney tissue sections of human
kidney biopsies in patients without AKI (normal) and with AKI. I: Average
immunostaining intensity score classified by luminal, apical, and interstitial
patterns for 112 patients with and without AKI. Data are expressed as
means  SEM. *P  0.05 Student’s t-test. Original magnification, 40.effacement of visceral epithelial cell foot processes onelectron microscopy (Figure 5, B and D); seven patients
also demonstrated signs of acute tubular injury (Figure
5E). Accordingly, all patients presented with nephrotic
syndrome and prominent proteinuria (9.86  1.84 g per
24 hours versus 10.14 1.22 g per 24 hours) (Figure 5E),
but some were associated with acute renal failure, as
indicated by SCr (0.77 0.07 mg/dL versus 4.35 0.71)
(Figure 5E). Fg immunoreactivity was significantly in-
creased in the luminal (Figure 5, F, I, and L), apical
(Figure 5, G, J, and L), and interstitial regions (Figure 5,
H, K, and L) in MCD patients who developed AKI, com-
pared with those who did not develop AKI. Approximately
a sixfold increase in luminal staining, a ninefold increase
in apical staining, and a 1.5-fold increase in interstitial
immunoreactivity of Fg was observed in MCD patients
with AKI, compared with those without AKI, which sug-
gests that expression patterns of Fg immunostaining in
the kidney can serve as an effective way to diagnose AKI
in MCD patients.
Discussion
The incidence of AKI is on the rise, the mortality rate from
AKI remains high, and studies have demonstrated that a
single event of AKI increases the risk for developing
chronic kidney disease.15–17 One of the major impedi-
ments in treating AKI is making an accurate diagnosis
that is early enough to alter the course of the disease by
allowing effective and timely intervention.4,7 An active
international effort is underway to identify sensitive, spe-
cific, and early diagnostic biomarkers in blood and urine
using rodent models of AKI,5,18,19 as well as clinical stud-
ies in humans.20,21 Here we show, first, that urinary Fg
serves as an early, sensitive and specific biomarker for
AKI in mice, rats and humans irrespective of whether the
injury is initiated by I/R or cisplatin administration and,
second, that immunoreactivity patterns of Fg effectively
differentiate patients with and without AKI.
Fibrinogen is a soluble 340-kDa trinodular dimeric gly-
coprotein with a hexameric structure composed of three
distinct pairs of disulfide-linked polypeptide chains: Fg,
Fg, and Fg.22,23 Beyond its central role in hemostasis,
Fg is also recognized as an acute-phase response pro-
tein and is significantly up-regulated on inflammatory
conditions in diverse pathological conditions.24–26 We
have previously reported Fg to be the second highest
gene up-regulated among 22,523 genes in rat kidney at
24 hours after 20 minutes of bilateral I/R injury.10 With the
present study, we provide further supportive evidence
that, after 30-minute bilateral I/R injury in rats, mRNA
levels of Fg, Fg, and Fg significantly increase at 24
hours, remain elevated till day 5, and then decline by day
7 (Table 1). Interestingly, after cisplatin administration the
Fg mRNA levels showed much higher increase (240
fold), compared with Fg (23-fold), at peak of injury (72
hours). It is possible that the differential regulation of
Fg/Fg mRNA is related to the mechanism of injury in
both models in which leukocyte-endothelial interactions
and endothelial dysfunction play a predominant role in
initiating injury in I/R,27,28 whereas cisplatin elicits epithe-
SEM. *
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reactive oxygen species, mitochondrial damage, and in-
flammation.14,29
Plasma levels of Fg increase severalfold on inflamma-
tion or tissue damage, and have been implicated as a risk
factor for cardiovascular disease,30 stroke,31 Alzheimer’s
disease,32 and chronic renal failure.33 The question as to
whether an increase in urinary Fg can serve as a sensi-
tive, specific and an early diagnostic indicator of a dis-
ease has not yet been effectively answered. We have
previously shown in a cross-sectional study of individuals
with and without kidney damage (n  25 per group) that
urinary Fg performed very well in differentiating between
patients with and without AKI or chronic kidney disease
(AUC-ROC  0.98).10 In the present study, urinary levels
of Fg increased significantly after kidney damage in rats
and mice, followed a temporal profile of incline/decline of
injury, and correlated with different grades of histopathol-
ogy (Figures 1 and 2). An approximately 60-fold increase
in urinary Fg levels at 3 hours after 30-minute bilateral I/R
injury could indicate early diagnostic capabilities of uri-
nary Fg, but could also be a consequence of plasma
leakage due to organ damage. Nonetheless, consistent
with these results, in seven patients with postoperative
AKI after abdominal aortic aneurysm surgery the SCr
levels tended to rise to50% of baseline values within 48
Figure 5. Differences in Fg immunostaining patterns in patients with MCD
biopsy sections in patients with MCD but not AKI (A, B, and F–H) or patients
following formalin fixation. B and D: Electron microscopic images of kidney
of immunofluorescence staining for Fg. E: Total urinary protein and SCr. L:
patterns for 14 patients with and without AKI. Data are expressed as means 
Scale bar  2 m.hours after surgery, whereas urinary Fg increased imme-diately in the postoperative period (AUC-ROC  0.68), in
concordance with tubular injury biomarkers such as uri-
nary KIM-1 (AUC-ROC  0.66) and NAG (AUC-ROC 
0.62). This suggests that the excretion of Fg in the urine
may be an early and sensitive indicator of tubulovascular
damage.
We studied patients undergoing abdominal aortic an-
eurysm surgery, a common setting for hospital-acquired
AKI due to ischemia. The relatively small numbers of
patients studied precluded definitive conclusions regard-
ing the potential of Fg, KIM-1, or NAG to serve as diag-
nostic tests. The results presented here should be re-
garded as preliminary, calling for larger scale validation
in larger cohorts. The observation that biomarkers rose
early in the postoperative setting suggests that earlier
identification of AKI may be possible with novel biomark-
ers such as Fg, KIM-1, and NAG. Because the distinction
between AKI and no AKI is based on SCr, which itself is
not a perfect marker of AKI, it should come as no surprise
that substantial overlap in biomarker values has been
observed in the present study and by others.20,34 Future
studies of Fg and other novel biomarkers of AKI should
be adequately powered to study moderate to severe AKI,
along with other clinical endpoints such as length of stay,
mortality, and fluid balance.35,36
Immunoreactive fibrin/Fg staining in vascular and ex-
without AKI. Shown are representative photomicrographs of human kidney
th MCD and AKI (C, D, and I–K). A and C: Kidney sections after PAS staining
s after uranyl acetate and lead citrate treatment. F–K: Representative images
immunostaining intensity score classified by luminal, apical, and interstitial
P  0.05 Student’s t-test. Original magnification: 20 (A and C); 40 (F–K).with or
with bo
section
Averagetravascular spaces of tissue occurs in a number of dis-
Fibrinogen as Biomarker of Kidney Injury 827
AJP September 2012, Vol. 181, No. 3eases such as atherosclerosis,37 kidney disease,38 tu-
mors,39 and inflammation,40 among others. In a rat model
of I/R injury, we have previously found distinct expression
patterns of Fg, Fg, and Fg chains in the renal tubular
epithelial cells, glomeruli, and interstitium at baseline and
during the regeneration in the injured kidney.10 Previous
studies conducted using human kidney biopsy speci-
mens have demonstrated membranous and interstitial
deposition of Fg in glomeruli in subacute and chronic
glomerulonephritis.41,42 Here, we report that in patients
with a pathological diagnosis of ATN (n  53) there was
no evidence of Fg immunoreactivity in the glomerulus or
vasculature, whereas the immunoreactivity in the apical
and luminal region of the tubules, as well as in the inter-
stitium, was markedly increased, compared with patients
without evidence of ATN (n  59). Tubular epithelial cells
normally do not reveal significant reactivity for fibrin, but
occasionally fine granular reactivity in the apical aspect
of the tubular epithelial cell cytoplasm can be noted,
sometimes but not necessarily in association with tubular
distension and/or luminal staining. Immunofluorescence
staining for Fg has traditionally been used to look for
vascular and glomerular inflammatory or thrombotic le-
sions in kidney biopsy material,43 but in many kidney
pathology laboratories this stain has not been used on a
routine basis for diagnosis of AKI. In particular, the use of Fg
immunofluorescence staining for evaluation of tubulointer-
stitial pathological processes in routine kidney biopsies has
never been investigated or reported. In our hands, however,
Fg immunofluorescence staining has become a very useful
tool, not only in identifying microangiopathic vascular and
glomerular changes, cellular crescents, or segmental fibrin-
oid necrosis, but also as an early and sensitive marker of
acute tubular injury.
The precise mechanism of development of acute renal
failure in the setting of MCD remains unknown, but hemo-
dynamic abnormalities in association with sudden and pro-
nounced hypoalbuminemia, intraparenchymal edema, and
pre-existing vascular disease and ischemia have all been
noted.44,45 Regardless of the specific mechanism, acute
tubular injury with or without epithelial cell necrosis is seen
in many patients with both MCD and AKI. The present study
showed a striking increase in immunoreactivity of Fg in
patients who developed AKI after MCD, compared with
patients with MCD who did not develop AKI. Such a finding
on immunofluorescence microscopy can be used as an aid
in the diagnosis of acute tubular injury in patients with MCD,
particularly in cases in which this diagnosis can be limited
by the sample size or subtle nature of histopathological
changes.
In summary, the present results demonstrate that the
increase in kidney tissue expression of Fg, as well as
urinary Fg, is conserved across species and thereby
serves as a sensitive and early diagnostic translational
biomarker for detection of acute kidney injury.
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